Clinical trial
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
NCT04732871 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- February 15, 2021
- Completion date
- February 19, 2027
- Enrollment
- 1,720 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.